Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
Sign Up to like & getrecommendations! Published in 2020 at "Gynecologic Oncology Reports"
DOI: 10.1016/j.gore.2020.100546
Abstract: Highlights • PI3K/AKT pathway alterations are frequently seen in ovarian cancer, providing rationale for targeted AKT inhibition.• AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian cancer was notable for dermatologic toxicity.• Best response… read more here.
Keywords: grade serous; high grade; inhibitor 2206; resistant high ... See more keywords
Akt inhibitor MK-2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine.
Sign Up to like & getrecommendations! Published in 2020 at "Oncology letters"
DOI: 10.3892/ol.2020.11300
Abstract: The PI3K/Akt pathway is an attractive therapeutic target in the treatment of pancreatic cancer, as it was demonstrated to be aberrantly regulated in pancreatic cancer cells. The present study aimed to investigate the therapeutic potential… read more here.
Keywords: inhibitor 2206; pancreatic cancer; akt inhibitor; cancer cell ... See more keywords